药物类型 单克隆抗体 |
别名 Claudin18.2 (CLDN18.2) humanized monoclonal antibody(MabSpace Biosciences (Suzhou) Co., Ltd.)、Claudin18.2 monoclonal antibody、Claudin18.2 monoclonal antibody(Mabspace Biosciences) + [5] |
靶点 |
作用方式 抑制剂 |
作用机制 CLDN18.2抑制剂(Claudin 18.2蛋白抑制剂)、ADCC(抗体依赖的细胞毒作用)、补体依赖的细胞毒性作用 |
在研适应症 |
非在研适应症- |
原研机构 |
非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评孤儿药 (美国) |
开始日期2023-10-31 |
申办/合作机构 |
开始日期2023-01-01 |
申办/合作机构 |
开始日期2022-01-14 |
申办/合作机构 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
CLDN18.2阳性胃食管交界处腺癌 | 临床3期 | - | 2023-10-31 | |
CLDN18.2阳性胃腺癌 | 临床3期 | - | 2023-10-31 | |
胃食管交界处腺癌 | 临床3期 | 中国 | 2023-09-01 | |
胃食管交界处腺癌 | 临床3期 | 韩国 | 2023-09-01 | |
转移性实体瘤 | 临床2期 | 中国 | 2020-08-13 | |
胰腺导管腺癌 | 临床2期 | 中国 | 2020-08-13 | |
晚期癌症 | 临床2期 | 美国 | 2020-05-28 | |
晚期恶性实体瘤 | 临床2期 | 美国 | 2020-05-28 | |
胃食管交界处癌 | 临床2期 | 美国 | 2020-05-28 | |
胰腺癌 | 临床2期 | 美国 | 2020-05-28 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床1/2期 | 32 | (築膚網壓選選夢窪廠遞) = All patients experienced treatment-related adverse events (TRAE). The most common TRAE were hypoalbuminaemia, nausea and vomiting, most of them were of CTC AE grade 1 or 2 and manageable. 範鏇壓餘糧蓋餘鏇繭積 (構餘鬱窪製壓遞觸鏇壓 ) 更多 | 积极 | 2024-09-16 | |||
临床1/2期 | 82 | (餘淵網憲餘襯鹽繭壓艱) = 願鏇壓餘鬱膚獵積築積 膚築簾願範觸廠鏇膚蓋 (鹹壓蓋繭鏇獵憲範範淵 ) 更多 | 积极 | 2024-05-24 | |||
临床1/2期 | 248 | (鹽網窪鏇製網衊鑰廠範) = Model simulated steady state trough concentration will achieve in vitro ADCC assay EC95 and in vivo MKN45-CLDN18.2 tumor growth inhibition model EC50 in most subjects following 6mg/kg Q3W and 4mg/kg Q2W. 鹹夢糧顧鬱窪積遞蓋鹹 (襯簾齋夢鹹獵壓簾膚繭 ) 更多 | 积极 | 2023-10-23 | |||
临床1/2期 | 64 | (選製夢網繭艱觸淵襯築) = nausea (70.3%), vomiting (53.1%) and hypoalbuminemia (75%) with grade 3 being 1.6% each 淵願顧製憲餘衊艱蓋鏇 (繭觸簾鹽築餘網憲鏇衊 ) | 积极 | 2023-10-23 | |||
(6 mg/kg in the dose expansion phase) | |||||||
临床1/2期 | 64 | osemitamab+CAPOX | (衊窪鬱選醖顧積製憲製) = Most of them were grade 1 or 2, only one patient experienced grade 3 nausea and vomiting. 餘齋鏇鑰鑰鑰簾膚鑰鹽 (膚鹽夢鏇蓋餘製鑰窪廠 ) | 积极 | 2023-06-30 | ||
临床1期 | 晚期癌症 一线 | 64 | Osemitamab+CAPOX | (願夢構淵壓範廠齋鏇夢) = Nausea (65.4%), vomiting (46.2%) and hypoalbuminemia (65.4%) were the most common adverse events related to TST001 at dose of 6mg/kg in 52 patients (3 patients in dose escalation and 49 patients in dose expansion), most of them were grade 1 or 2 (only one patient experienced grade 3 nausea and vomiting, and one experienced grade 3 hypoalbuminemia). 襯餘襯構艱窪襯願選鬱 (簾製觸築憲糧壓構顧鬱 ) | 积极 | 2023-05-26 | |
Osemitamab+CAPOX | |||||||
临床1期 | 胃食管交界处癌 一线 | 26 | CAPOX+TST001 | (獵願獵廠膚製艱窪願餘) = Most are grade 1-2, including nausea, hypoalbuminemia, anemia, vomiting, and elevated AST 醖繭築選夢鏇齋繭醖製 (襯簾憲築網顧製鏇顧構 ) | 积极 | 2022-06-02 |